XBiotech (NASDAQ:XBIT) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• XBiotech shares fell below their 200‑day moving average, trading as low as $2.31 versus the 200‑day SMA of $2.53, a bearish technical signal.
• Analysts rate the stock a "Sell" — Weiss Ratings reiterated a "sell (d-)" and the MarketBeat consensus is currently Sell.
• Fundamentals remain weak: XBiotech is a clinical‑stage biopharma (lead drug Xilonix) with negative recent EPS (−$0.88), a market cap of about $70M and a negative P/E, indicating elevated risk for investors.

Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.53 and traded as low as $2.31. XBiotech shares last traded at $2.31, with a volume of 5,259 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a "sell (d-)" rating on shares of XBiotech in a research note on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Sell".

XBiotech Price Performance

The firm's 50 day simple moving average is $2.45 and its 200-day simple moving average is $2.53. The company has a market cap of $70.43 million, a price-to-earnings ratio of -2.41 and a beta of 0.87.

XBiotech (NASDAQ:XBIT - Get Free Report) last posted its earnings results on Friday, March 13th. The biopharmaceutical company reported ($0.88) EPS for the quarter.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Persistent Asset Partners Ltd acquired a new stake in shares of XBiotech in the fourth quarter valued at approximately $32,000. Bank of America Corp DE grew its position in shares of XBiotech by 41.5% during the second quarter. Bank of America Corp DE now owns 18,208 shares of the biopharmaceutical company's stock worth $54,000 after acquiring an additional 5,344 shares during the last quarter. XTX Topco Ltd acquired a new position in shares of XBiotech in the 2nd quarter valued at $61,000. BNP Paribas Financial Markets increased its holdings in shares of XBiotech by 27.1% in the 2nd quarter. BNP Paribas Financial Markets now owns 20,729 shares of the biopharmaceutical company's stock valued at $62,000 after acquiring an additional 4,416 shares during the period. Finally, Jane Street Group LLC purchased a new stake in XBiotech in the 2nd quarter valued at $75,000. Institutional investors and hedge funds own 55.70% of the company's stock.

About XBiotech

XBiotech Inc is a clinical-stage biopharmaceutical company developing human antibodies to treat cancer and other inflammatory-driven diseases. The company's core technology, the True Human™ antibody platform, enables the discovery and development of monoclonal antibodies that mimic the human immune response without the need for genetic humanization. XBiotech's lead therapeutic candidate targets interleukin-1 alpha (IL-1α), a key mediator of inflammation associated with tumor growth and chronic disease.

The company's most advanced program, Xilonix® (MABp1), is a first-in-class anti-IL-1α antibody that has completed Phase 3 clinical trials in metastatic colorectal cancer patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.